• 1

 

Recent published funding opportunities:

Funding Number Funding Title
RFA CA 16 502 Limited Competition: The Chernobyl Tissue Bank - Coordinating Center (U24)
RFA CA 16 015 U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer (R21)
RFA CA 16 014 Cancer Target Discovery and Development Network (U01)
RFA AA 17 006 U.S.-Russia Bilateral Collaborative Research Partnerships (CRP) on the Prevention and Treatment of HIV/AIDS and HIV-Associated Comorbidities (R01)
PAR 16 338 Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)
PAR 16 336 Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21)
PAR 16 337 Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)
PAR 16 318 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)
PAR 16 317 Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01)
RFA AA 17 004 Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24)
RFA AA 17 005 Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)
RFA AA 17 003 Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01)
PAR 16 291 Integrative Research on Polysubstance Abuse and Addiction (R21/R33)
PAR 16 292 Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21)
PAR 16 293 The NCI Transition Career Development Award (K22)
RFA AI 16 038 Silencing of HIV-1 Proviruses (R61/R33)
PAR 16 284 Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)
PAR 16 277 Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)
PAR 16 281 Planning Grant for Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D71)
PA 16 232 Prescription Drug Abuse (R21)
PAR 16 278 Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)
PAR 16 280 Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11)
PAR 16 279 Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43)
PAR 16 276 Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)
PAR 16 275 Serious Adverse Drug Reaction Research (R01)
PAR 16 274 Serious Adverse Drug Reaction Research (R21)
PAR 16 266 Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)
PAR 16 261 Methodology and Measurement in the Behavioral and Social Sciences (R21)
PA 16 258 Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21)
PAR 16 260 Methodology and Measurement in the Behavioral and Social Sciences (R01)
PAR 16 256 Cancer-related Behavioral Research through Integrating Existing Data (R01)
PAR 16 255 Cancer-related Behavioral Research through Integrating Existing Data (R21)
PAR 16 257 Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21)
PAR 16 250 Building Evidence: Effective Palliative/End of Life Care Interventions (R01)
PAR 16 234 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01)
PAR 16 248 Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21)
PA 16 252 Gene Fusions in Pediatric Sarcomas (R21)
PAR 16 249 Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01)
PA 16 251 Gene Fusions in Pediatric Sarcomas (R01)
PA 16 233 Prescription Drug Abuse (R01)
PAR 16 246 Neural Regulation of Cancer (R21)
PAR 16 245 Neural Regulation of Cancer (R01)
RFA HG 16 010 Clinical Sequencing Evidence-Generating Research (CSER2) - Clinical Sites (U01)
RFA HG 16 011 Clinical Sequencing Evidence-Generating Research (CSER2) - Clinical Sites with Enhanced Diversity (U01)
PAR 16 228 Metabolic Reprogramming to Improve Immunotherapy (R01)
PA 16 230 Non-healing Ulcerative Wounds in Aging (R01)
PAR 16 229 Metabolic Reprogramming to Improve Immunotherapy (R21)
PAR 16 227 The Role of Mobile Genetic Elements in Cancer (R01)
PAR 16 224 NIDA Research Education Program for Clinical Researchers and Clinicians (R25)
PAR 16 226 The Role of Mobile Genetic Elements in Cancer (R21)

 

  • 1

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants